Poly(pro-drug) Material Sustained Drug Release via Cleavable Linkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering estrogen for extended periods in medical applications, such as spinal cord injuries, are limited by short release durations and require frequent replacements or carrier polymers, which are not ideal for long-term therapeutic effects.
Innovation Solution
A poly(pro-drug) material comprising polymers with therapeutic compounds like estrogen, curcumin, or fingolimod, linked via cleavable ester, urethane, or carbonate groups, and biodegradable hydrocarbyl chains, which degrades to release these compounds at a controlled rate of 0.01-0.25% per day, allowing for prolonged therapeutic effects without the need for frequent replacements.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional estrogen delivery methods (diffusion-based or short-oligomer pro-drugs) are used, then the device can be manufactured and implanted, but the release duration is limited to days or weeks requiring frequent replacements
Solution Approach 1:
The patent creates a composite polymeric material where estrogen molecules are covalently bonded to a polymer backbone through cleavable linker groups. This composite structure combines the polymer matrix with the therapeutic agent, enabling sustained release over months to years rather than days or weeks. The polymer-estrogen conjugate maintains structural integrity while allowing controlled degradation and drug release.
Solution Approach 2:
The patent modifies the chemical parameters of estrogen by converting it from a small molecule into a polymeric pro-drug conjugate. This parameter change includes increasing molecular weight, changing solubility characteristics, and introducing cleavable chemical bonds that control release kinetics. The polymer chain length and linker chemistry are tuned to achieve desired release durations of months to years.
2Reliability
If frequent device replacements are implemented to maintain therapeutic effect, then adequate drug delivery is achieved, but patient burden and medical resource utilization increase
Solution Approach 1:
The polymeric pro-drug structure enables continuous drug release over extended periods (months to years) through controlled degradation of the polymer-estrogen conjugate. The cleavable linker groups progressively release estrogen as the polymer degrades, providing uninterrupted therapeutic action without requiring device removal or replacement, thus maintaining reliability while eliminating the need for frequent interventions.
3Duration of action of moving object
If carrier polymers are used to extend release duration, then release time is prolonged, but the system requires additional components increasing complexity
Solution Approach 1:
The patent merges the carrier polymer and therapeutic agent (estrogen) into a single integrated polymeric pro-drug molecule. Instead of using a separate carrier polymer that physically entraps or adsorbs estrogen, the estrogen is covalently bonded to the polymer backbone, combining the carrier and drug into one molecular entity. This reduces system complexity from multiple components to a single conjugated structure while achieving extended release.
4Ease of manufacture
If short-oligomer pro-drugs are used, then the formulation can be manufactured, but the release duration is limited and chain branching reduces control
Solution Approach 1:
The patent segments the polymer chain into repeating units, each containing an estrogen molecule linked to the polymer backbone through cleavable linker groups. This segmented structure allows systematic control of drug loading and release kinetics. By using linear polymer chains with regular spacing of drug moieties, the patent achieves better control over degradation and release compared to branched oligomers, while maintaining manufacturability through established polymerization techniques.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The poly(pro-drug) material provides a sustained release of therapeutic compounds over several months to years, enhancing therapeutic efficacy and reducing the frequency of device replacement, while maintaining biocompatibility and safety.
Implementation Method 1
R2 includes one or more cleavable linker compounds... In some embodiments, the cleavable linker compound includes an ester, a urethane, a carbonate
Data Source
AI summary
The poly(pro-drug) material includes one or more alternating therapeutic compounds and biodegradable hydrocarbyl groups. The therapeutic compounds and biodegradable hydrocarbyl groups are separated by cleavable linker compounds. The therapeutic compounds, such as estrogen, curcumin, and fingolimod, include a plurality of substitutable functional groups that provide reaction sites for complexing with the cleavable linkers and in turn one or more polymers, such that the poly(pro-drug) material ends up composed of the therapeutic compound itself. In aqueous media and at physiological temperature and pH, the poly(pro-drug) materials degrade to release the therapeutic compounds from the material with a zero-order release profile, Advantageously, the poly(pro-drug) materials release the therapeutic compounds on time scales of years. The poly(pro-drug) materials also exhibit reduced to allow for prolonged implantation within a patient. These materials are enticing for a myriad of biomedical applications, including veterinary medicine, cancer treatments, birth control, and hormone replacement therapy.